All In Biotech

Drug Trial Radar · NCT05187793

Study of Efficacy of Different Treatment Regimens of Olokizumab

A Multicenter, Open-label, Randomized Study of the Efficacy and Safety of Artlegia (INN: Olokizumab) New Dosing Regimen in Patients With Coronavirus Infection (COVID-19) With Signs of Hyperinflammation

Last checked: Nov 20, 2026Latest source record: Feb 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

198

Actual

Start

Jul 8, 2021

Primary completion

Oct 31, 2022

Study completion Apr 2023

Sponsor

Lead sponsor
R-PharmIndustry
Sponsor type
Industry
Collaborators
Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor; Group of companies Medsi, JSС
First posted
Jan 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation. This study is a multicentre, open-label, randomized, comparative, parallel group, active-controlled clinical trial.

Conditions

  • COVID-19

Interventions

  • OlokizumabDrug

    Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL

  • Standard therapyDrug

    Standard treatment including: * Baricitinib, 4 mg, film coated tablets * Favipiravir, 200 mg, film coated tablets * Dexamethasone IV or IM OR Methylprednisolone IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical recovery rate at day 7Time frame: Up to day 7

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • State Budgetary Healthcare Institution "City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department"

    Moscow, Russia

  • Federal State Budgetary Institution "Central Clinical Hospital with a Polyclinic" of Presidential Administration of the Russian Federation

    Moscow, Russia

  • State Budgetary Healthcare Institution "City Clinical Hospital № 52 of Moscow Healthcare Department"

    Moscow, Russia

  • State Budgetary Healthcare Institution "Infectious Diseases Hospital No. 1 of Moscow Healthcare Department"

    Moscow, Russia

  • State Budgetary healthcare Institution of the Voronezh region "Voronezh Regional Clinical Hospital No. 1"

    Voronezh, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.